cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1259Research ArticleРЕЗУЛЬТАТЫ МЕЖДУНАРОДНЫХ ИССЛЕДОВАНИЙРезультаты исследования HYVET: значение для клинической практикиHYVET Study results: importance for clinical practiceНедогодаС. В.NedogodaS. V.nedogodasv@rambler.ruВолгоградский государственный медицинский университет, ВолгоградVolgograd State Medical University. Volgograd200820102008757680Copyright © Недогода С.В., 20082008Недогода С.В.Nedogoda S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1259

HYVET Study was aimed at assessing the effects of indapamide SR (1,5 mg/d), as monotherapy or combined with an ACE inhibitor perindopril (2-4 mg/d), compared to placebo, on the risk of stroke and other cardiovascular events in arterial hypertension patients aged over 80 years. Active indapamide SR therapy significantly reduced the risk of fatal and non-fatal stroke by 30%, fatal and non-fatal heart failure – by 64%, fatal stroke – by 39%, allcause mortality – by 21%, with additional reduction in the risk of cardiovascular and non-cardiovascular mortality, coronary heart disease and chronic heart failure mortality.

HYVETартериальная гипертензияочень пожилые пациентыиндапамид ретардHYVET Studyarterial hypertensionvery old patientsindapamide retardReferencesAmery A. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 589–92.Amery A. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 589–92.Baguet JP, Robitail S, Boyer L, et al. A Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Am J Cardiovasc Drugs 2005; 5(2): 131–40.Baguet JP, Robitail S, Boyer L, et al. A Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Am J Cardiovasc Drugs 2005; 5(2): 131–40.Boshuizen HC, Izaks GJ, van Buuren S, Ligthart GJ. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ 1998; 316:1780–4.Boshuizen HC, Izaks GJ, van Buuren S, Ligthart GJ. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ 1998; 316:1780–4.Bulpitt C. The Hypertension in the very Elderly Trial (HYVET). Rational, methology and comparison with previous trials. Drugs Aging 1994; 5: 171–83.Bulpitt C. The Hypertension in the very Elderly Trial (HYVET). Rational, methology and comparison with previous trials. Drugs Aging 1994; 5: 171–83.Dahlof B, Lindholm L, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOPHypertension). Lancet 1991; 338: 1281–5.Dahlof B, Lindholm L, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOPHypertension). Lancet 1991; 338: 1281–5.Fletcher A. Epidemiology of Hypertension in the elderly. J Hypertens 1994; 12(Suppl. 6): 2.Fletcher A. Epidemiology of Hypertension in the elderly. J Hypertens 1994; 12(Suppl. 6): 2.Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.Hansson L. Study on Cognition and Prognosis in the Elderly (SCOPE). Blood pressure 1999; 8: 177–83.Hansson L. Study on Cognition and Prognosis in the Elderly (SCOPE). Blood pressure 1999; 8: 177–83.London G, Asmar R, Schmieder R, Calvo C. Antihypertensive efficacy of Indapamide SR vs candesartan and amlodipine in hypertensive patients in isolated hypertensive patients. Am J Hypertens 2004; 17: 183A.London G, Asmar R, Schmieder R, Calvo C. Antihypertensive efficacy of Indapamide SR vs candesartan and amlodipine in hypertensive patients in isolated hypertensive patients. Am J Hypertens 2004; 17: 183A.Marre M, Fernandez M, Puig J. Indapamide SR is efficient as enalapril in reducing microalbuminuria in type 2 diabetic hypertensive patients. J Hypertens 2002; 20(Suppl.4): S163.Marre M, Fernandez M, Puig J. Indapamide SR is efficient as enalapril in reducing microalbuminuria in type 2 diabetic hypertensive patients. J Hypertens 2002; 20(Suppl.4): S163.Psaty BM. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739–45.Psaty BM. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739–45.Sander GE. High Blood Pressure in the Geriatric Population: treatment consideration. Am J Geriatr Cardiol 2002; 11(3): 223–32.Sander GE. High Blood Pressure in the Geriatric Population: treatment consideration. Am J Geriatr Cardiol 2002; 11(3): 223–32.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.Staessen J, Gasthuisberg C. Blood pressure in very old subjects: a dilemma for the clinical. Eur Heart J 1998; 19: 1743–4.Staessen J, Gasthuisberg C. Blood pressure in very old subjects: a dilemma for the clinical. Eur Heart J 1998; 19: 1743–4.Карпов Ю.А. Лечение артериальной гипертонии у пожилых: мифический риск и доказанная помощь. Клин фармакол тер 1995; 3: 34–6.Карпов Ю.А. Лечение артериальной гипертонии у пожилых: мифический риск и доказанная помощь. Клин фармакол тер 1995; 3: 34–6.Карпов Ю.А. Особенности лечения сердечно-сосудистых, заболеваний у пожилых больных. Е.В. Сорокин. РМЖ 2003; 11(19): 1072–6.Карпов Ю.А. Особенности лечения сердечно-сосудистых, заболеваний у пожилых больных. Е.В. Сорокин. РМЖ 2003; 11(19): 1072–6.Кобалава Ж.Д. Систолическое давление – ключевой показатель диагностики, контроля и прогнозирования риска артериальной гипертонии. Возможности блокады рецепторов ангиотензина II. Клин фармак тер 2000; 12–8.Кобалава Ж.Д. Систолическое давление – ключевой показатель диагностики, контроля и прогнозирования риска артериальной гипертонии. Возможности блокады рецепторов ангиотензина II. Клин фармак тер 2000; 12–8.Комисаренко И.А. Целесообразность медикаментозной терапии и приверженность к лечению пожилых пациентов с артериальной гипертонией. Клин геронт 2002; 9: 38–41.Комисаренко И.А. Целесообразность медикаментозной терапии и приверженность к лечению пожилых пациентов с артериальной гипертонией. Клин геронт 2002; 9: 38–41.Мартынов А.И. Артериальная гипертензия у лиц пожилого и старческого возраста (по материалам IX Европейской конференции по артериальной гипертензии. Клин геронт 2002; 1: 74–9.Мартынов А.И. Артериальная гипертензия у лиц пожилого и старческого возраста (по материалам IX Европейской конференции по артериальной гипертензии. Клин геронт 2002; 1: 74–9.Mattila K, Haavisto M, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old. Br Med J 1988; 296(6626): 887–9.Mattila K, Haavisto M, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old. Br Med J 1988; 296(6626): 887–9.Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. INDANA Group. Lancet 1999; 353(9155): 793–6.Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. INDANA Group. Lancet 1999; 353(9155): 793–6.Beckett N. Progress report of HYVET. J Hypertens 2007; 25(Supp 2): S233.Beckett N. Progress report of HYVET. J Hypertens 2007; 25(Supp 2): S233.

The authors declare that there are no conflicts of interest present.